OmniAb, Inc. (NASDAQ:OABI) Insider Charles S. Berkman Sells 25,489 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 25,489 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. This trade represents a 6.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

OmniAb Price Performance

OABI opened at $3.20 on Thursday. The company has a market capitalization of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10. The business’s 50-day moving average price is $3.68 and its two-hundred day moving average price is $4.06. OmniAb, Inc. has a 1 year low of $3.16 and a 1 year high of $6.55.

Institutional Investors Weigh In On OmniAb

Several institutional investors have recently bought and sold shares of OABI. CWC Advisors LLC. bought a new position in shares of OmniAb during the 3rd quarter worth approximately $54,000. Walleye Capital LLC bought a new stake in shares of OmniAb in the third quarter worth $61,000. Intech Investment Management LLC acquired a new position in OmniAb during the third quarter worth $70,000. China Universal Asset Management Co. Ltd. grew its position in OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC increased its stake in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after buying an additional 2,744 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

Analyst Ratings Changes

OABI has been the topic of several research analyst reports. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.